| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCR6 |
| Uniprot No | O00574 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-342aa |
| 氨基酸序列 | MAEHDYHEDYGFSSFNDSSQEEHQDFLQFSKVFLPCMYLVVFVCGLVGNSLVLVISIFYHKLQSLTDVFLVNLPLADLVFVCTLPFWAYAGIHEWVFGQVMCKSLLGIYTINFYTSMLILTCITVDRFIVVVKATKAYNQQAKRMTWGKVTSLLIWVISLLVSLPQIIYGNVFNLDKLICGYHDEAISTVVLATQMTLGFFLPLLTMIVCYSVIIKTLLHAGGFQKHRSLKIIFLVMAVFLLTQMPFNLMKFIRSTHWEYYAMTSFHYTIMVTEAIAYLRACLNPVLYAFVSLKFRKNFWKLVKDIGCLPYLGVSHQWKSSEDNSKTFSASHNVEATSMFQL |
| 预测分子量 | 40.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCR6重组蛋白的3篇代表性文献摘要：
1. **标题**：Structural characterization of recombinant human CXCR6 in lipid bilayers
**作者**：Smith A, et al.
**摘要**：通过NMR解析CXCR6重组蛋白在脂质双分子层中的三维结构，揭示其与趋化因子CXCL16结合的构象变化，为靶向药物设计提供结构基础。
2. **标题**：CXCR6 recombinant protein enhances T cell migration in liver fibrosis models
**作者**：Wang Y, et al.
**摘要**：体外表达CXCR6重组蛋白，证明其介导CD8+ T细胞向纤维化肝脏组织迁移的机制，提示其在免疫调节中的潜在治疗价值。
3. **标题**：Functional analysis of CXCR6 variants using recombinant protein expression systems
**作者**：Lee H, et al.
**摘要**：构建哺乳动物细胞表达系统制备CXCR6重组蛋白，发现特定基因突变导致受体信号传导异常，与自身免疫疾病发病相关。
注：以上内容为模拟文献摘要，实际文献需通过PubMed/Google Scholar检索关键词"CXCR6 recombinant protein"获取。
CXCR6. or C-X-C chemokine receptor type 6. is a G protein-coupled receptor (GPCR) that binds specifically to the chemokine CXCL16. It plays a critical role in immune cell trafficking, inflammation, and tissue homeostasis. Structurally, CXCR6 features seven transmembrane domains, a hallmark of GPCRs, and is expressed on various immune cells, including T cells, natural killer T (NKT) cells, and dendritic cells. Its interaction with CXCL16. a membrane-bound or soluble chemokine, facilitates leukocyte recruitment to sites of inflammation, tumor microenvironments, and lymphoid tissues. CXCR6 is also implicated in diseases such as cancer, viral infections (e.g., HIV, hepatitis), and autoimmune disorders, making it a therapeutic target of interest.
Recombinant CXCR6 protein is engineered for research and drug discovery, typically produced in heterologous expression systems like mammalian (e.g., HEK293) or insect cells to ensure proper post-translational modifications and functional folding. The recombinant form often includes tags (e.g., FLAG, His-tag) for purification and detection. It enables in vitro studies of receptor-ligand interactions, signaling pathways (e.g., MAPK/ERK, PI3K/Akt), and mechanisms underlying CXCR6-mediated immune responses. Researchers use it to screen inhibitors/agonists, map binding domains, or study cross-talk with other receptors (e.g., co-receptors in HIV entry).
Recent studies highlight CXCR6's role in cancer progression by promoting tumor-infiltrating lymphocyte (TIL) recruitment and modulating immune evasion. In viral infections, CXCR6-expressing CD4+ T cells are reservoirs for HIV persistence. Its involvement in liver fibrosis and neurodegenerative diseases further underscores its biomedical relevance. Structural studies of recombinant CXCR6. often combined with cryo-EM or X-ray crystallography, aid in designing targeted therapies. However, challenges remain in understanding its context-dependent signaling and developing tissue-specific modulators.
×
